LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Triple Negative Breast Cancer
Interventions: BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes LN-145|BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes LN-145-S1|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration
Sponsor: M.D. Anderson Cancer Center
Collaborators: Iovance Biotherapeutics, Inc.|National Cancer Institute (NCI)